Community Research and Development Information Service - CORDIS

H2020

Fucoderm Report Summary

Project ID: 744737

Periodic Reporting for period 1 - Fucoderm (An effective, side effect-free topical emollient treatment for atopic dermatitis made from a sustainably procured seaweed extract)

Reporting period: 2016-12-01 to 2017-03-31

Summary of the context and overall objectives of the project

GlycoMar intends to develop a novel topical cream for the management of mild to moderate eczema. The new product, ‘Fucobase’ will be suitable for long-term use and safe for both adults and children. The key objectives of the project are to finalise the Fucobase formulation, validate its safety and efficacy in humans, and commercialise the product as a CE certified medical device.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Throughout the duration of the Phase I project, GlycoMar reviewed the product development plan, secured partners for further product development, expanded their knowledge of the eczema market and established a commercialisation strategy. The Phase 1 feasibility assessment established that a development plan for the Fucobase product is technically and commercially viable, and that implementation of an industrialisation and commercialisation plan should be pursued. SME Instrument Phase 2 funding could provide the correct amount of funding and support to allow the stated activities to be implemented successfully.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The proposed Fucobase product will provide mild to moderate eczema sufferers, with an effective, natural and universal treatment. Unlike many existing products, it will be suitable for use in both adults and children, due to minimal side effects. Fucobase will therefore contribute to a sustainable and innovative healthcare system in Europe by reducing the large medical and social costs caused by this common disease.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top